EPITRACKER FIBROTIC DISEASE
& THERAPEUTICS PROGRAM
Treating Nonalcoholic Steatohepatitis (NASH) and Other Fibrotic Diseases
Nonalcoholic steatohepatitis (NASH) is soon to become the world's leading cause of liver transplants. Nonalcoholic fatty liver disease (NAFLD) and its advanced form, NASH, are liver diseases involving abnormal fat deposition, inflammation and fibrosis. NASH can result in liver cirrhosis, hepatocellular carcinoma, and transplants.
Today, there are no effective treatments for NASH. The lack of a cure is due, in part, to the lack of knowledge about other species that may develop similar liver diseases.
Today, there are no effective treatments for NASH. The lack of a cure is due, in part, to the lack of knowledge about other species that may develop similar liver diseases.
Wild Dolphins & NASH
Interestingly, older bottlenose dolphins are naturally susceptible to NAFLD and NASH, which has been found in approximately 1 in 6 dolphins in the wild. By studying tissue-based changes in archived dolphin livers and pairing those changes with metabolomic, complex lipid, and genomic profiles, Epitracker is discovering molecules that may aid in early, blood-based detection and treatment of NAFLD/NASH. Thanks to dolphins, we are also gaining a valuable understanding of the pathophysiology of NASH that appears to be present in both dolphins and humans.
Our NASH compound library has approximately 25 small molecules.
Our NASH compound library has approximately 25 small molecules.
ETI-101, ETI-039, ETI-059 and ETI-070 for NASH & OTHER FIBROTIC DISEASES
Our NASH compound library has approximately 25 small molecules that are demonstrating promise as biomarkers, therapeutic targets, and/or therapeutic candidates for NASH.
Within Epitracker's current product development pipeline, ETI-101, ETI-039, ETI-035, ETI-059 and ETI-070 have demonstrated antifibrotic activities, relevant to NASH and other fibrotic diseases, that outperformed current leading NASH treatment candidates, including PPAR and FXR agonists. We have successfully demonstrated in efficacy studies less severe liver fibrosis in an ETI-101-treated group versus non-treated controls in a NASH model.
Within Epitracker's current product development pipeline, ETI-101, ETI-039, ETI-035, ETI-059 and ETI-070 have demonstrated antifibrotic activities, relevant to NASH and other fibrotic diseases, that outperformed current leading NASH treatment candidates, including PPAR and FXR agonists. We have successfully demonstrated in efficacy studies less severe liver fibrosis in an ETI-101-treated group versus non-treated controls in a NASH model.